Literature DB >> 28913572

Establishment of S100A8 Transgenic Rats to Understand Innate Property of S100A8 and Its Immunological Role.

Kohki Okada1, Hiroshi Itoh2, Yasuhiko Kamikubo3, Souichi Adachi3, Masaki Ikemoto4.   

Abstract

The innate properties of S100A8 as a regulator in acute inflammation have not yet been elucidated in detail. Our aims are to newly establish S100A8 transgenic rats (Tg-S100A8) and to elucidate the immunological functions of S100A8. Following the treatment with 5% dextran sulfate sodium for 1 week, the body weight in Tg-S100A8 weakly decreased after the start; however, that in Japanese Wistar rats (WT) significantly decreased in the end. The serum level of CRP in Tg-S100A8 was significantly lower than that in WT, although the concentration of CRP apparently increased in both Tg-S100A8 and WT. The dynamic mobility of S100A8 and S100A9 in macrophages was microscopically observed using fluorescent immunological staining, in which the S100A9 was dominantly expressed in many macrophages in the rectal tissue of WT. As determined by PCR and real-time PCR, the levels of S100A8 messenger RNA (mRNA) in several organ tissues of the Tg-S100A8, such as heart and small intestine, were apparently higher than those of WT, respectively. The expression of IL-6 and TNF-α mRNAs was negatively regulated in main organ tissues of the large colon of Tg-S100A8 followed by down-regulation of IL-6 protein. An important result was that the expression of S100A8 mRNA was strongly induced in many macrophages of Tg-S100A8, whereas that of some inflammatory cytokine mRNAs described above were significantly reduced. Tg-S100A8 has potential as a useful experimental model rat not only for investigating the innate properties of S100A8 as a regulator, but also for clarifying its functional role in immune cells from a myeloid origin, particularly macrophages.

Entities:  

Keywords:  anti-inflammatory protein; inflammatory bowel diseases; interleukin-6; macrophages; transgenic rats

Mesh:

Substances:

Year:  2018        PMID: 28913572     DOI: 10.1007/s10753-017-0664-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  34 in total

Review 1.  Non-invasive investigation of inflammatory bowel disease.

Authors:  J A Tibble; I Bjarnason
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Intrinsic function of S100A8/A9 complex as an anti-inflammatory protein in liver injury induced by lipopolysaccharide in rats.

Authors:  Masaki Ikemoto; Hiroshi Murayama; Hiroshi Itoh; Masayuki Totani; Masatoshi Fujita
Journal:  Clin Chim Acta       Date:  2006-08-24       Impact factor: 3.786

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Dynamic mobility of immunological cells expressing S100A8 and S100A9 in vivo: a variety of functional roles of the two proteins as regulators in acute inflammatory reaction.

Authors:  Akiko Koike; Satoshi Arai; Sachiko Yamada; Akiko Nagae; Naoko Saita; Hiroshi Itoh; Shinji Uemoto; Masayuki Totani; Masaki Ikemoto
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

5.  Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Sigrid Odegard; Magne K Fagerhol; Robert Landewé; Désirée van der Heijde; Till Uhlig; Petter Mowinckel; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

6.  S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-κB activation in gastric cancer cells.

Authors:  Chae Hwa Kwon; Hyun Jung Moon; Hye Ji Park; Jin Hwa Choi; Do Youn Park
Journal:  Mol Cells       Date:  2013-02-26       Impact factor: 5.034

7.  Modulation of gene expression induced in human epidermis by environmental stress in vivo.

Authors:  Claire Marionnet; Françoise Bernerd; Arnaud Dumas; Franck Verrecchia; Karine Mollier; Delphine Compan; Bruno Bernard; Morad Lahfa; Jacques Leclaire; Chantal Medaisko; Bruno Mehul; Sophie Seité; Alain Mauviel; Louis Dubertret
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

8.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

9.  Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD.

Authors:  Donata Lissner; Michael Schumann; Arvind Batra; Lea-Isabel Kredel; Anja A Kühl; Ulrike Erben; Claudia May; Jörg-Dieter Schulzke; Britta Siegmund
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

10.  Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis.

Authors:  Min Jeoung Lee; Jin-Ku Lee; Ji Won Choi; Chang-Seok Lee; Ji Hyun Sim; Chung-Hyun Cho; Kwang-Ho Lee; Ik-Hyun Cho; Myung-Hee Chung; Hang-Rae Kim; Sang-Kyu Ye
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

View more
  3 in total

1.  Carbonic Anhydrase III Has Potential as a Biomarker for Experimental Colitis and Functions as an Immune Regulator by Inhibiting Inflammatory Cytokine Secretion.

Authors:  Kohki Okada; Masaki Ikemoto
Journal:  Biology (Basel)       Date:  2022-03-23

2.  Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease.

Authors:  Takuya Kotani; Masaki Ikemoto; Shogo Matsuda; Ryota Masutani; Tohru Takeuchi
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

3.  Circulating S100A8/A9 is potentially a biomarker that could reflect the severity of experimental colitis in rats.

Authors:  Kohki Okada; Hiroshi Itoh; Masaki Ikemoto
Journal:  Heliyon       Date:  2020-02-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.